SU1217258A3 - Способ получени производных 2-гуанидино-4-гетероарилтиазола или их фармацевтически приемлемых кислотно-аддитивных солей - Google Patents
Способ получени производных 2-гуанидино-4-гетероарилтиазола или их фармацевтически приемлемых кислотно-аддитивных солей Download PDFInfo
- Publication number
- SU1217258A3 SU1217258A3 SU823493197A SU3493197A SU1217258A3 SU 1217258 A3 SU1217258 A3 SU 1217258A3 SU 823493197 A SU823493197 A SU 823493197A SU 3493197 A SU3493197 A SU 3493197A SU 1217258 A3 SU1217258 A3 SU 1217258A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- mmol
- acid
- mixture
- imidazolyl
- pharmaceutically acceptable
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims abstract description 6
- 239000000654 additive Substances 0.000 title claims abstract description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 27
- 239000002253 acid Substances 0.000 claims abstract description 13
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000009835 boiling Methods 0.000 claims abstract description 4
- OKGXJRGLYVRVNE-UHFFFAOYSA-N diaminomethylidenethiourea Chemical compound NC(N)=NC(N)=S OKGXJRGLYVRVNE-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000000996 additive effect Effects 0.000 claims abstract description 3
- 239000003960 organic solvent Substances 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 239000011541 reaction mixture Substances 0.000 claims description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 27
- 239000007787 solid Substances 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 7
- 229960001340 histamine Drugs 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- -1 4-Acetyl-4-methyl imidazole Chemical compound 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000739 antihistaminic agent Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 4
- 108010079943 Pentagastrin Proteins 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 4
- 229960000444 pentagastrin Drugs 0.000 description 4
- 238000006303 photolysis reaction Methods 0.000 description 4
- 230000015843 photosynthesis, light reaction Effects 0.000 description 4
- 239000010453 quartz Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- TUFOJIVMBHBZRQ-UHFFFAOYSA-N 1-(1h-imidazol-5-yl)ethanone Chemical compound CC(=O)C1=CN=CN1 TUFOJIVMBHBZRQ-UHFFFAOYSA-N 0.000 description 3
- HEUBFSYOZRPRTD-UHFFFAOYSA-N 1-(2,5-dimethyl-1h-imidazol-4-yl)ethanone Chemical compound CC(=O)C=1NC(C)=NC=1C HEUBFSYOZRPRTD-UHFFFAOYSA-N 0.000 description 3
- MZJZNADJWQEIIG-UHFFFAOYSA-N 1-(2-methyl-1h-imidazol-5-yl)ethanone Chemical compound CC(=O)C1=CN=C(C)N1 MZJZNADJWQEIIG-UHFFFAOYSA-N 0.000 description 3
- WQNVXLSZFIYEDC-UHFFFAOYSA-N 1-(4-methylimidazol-1-yl)ethanone Chemical compound CC(=O)N1C=NC(C)=C1 WQNVXLSZFIYEDC-UHFFFAOYSA-N 0.000 description 3
- VSEUYEAKIAUEHZ-UHFFFAOYSA-N 3-bromo-4-ethoxybut-3-en-2-one Chemical compound CCOC=C(Br)C(C)=O VSEUYEAKIAUEHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 3
- 229960001380 cimetidine Drugs 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 150000002357 guanidines Chemical class 0.000 description 3
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 3
- 210000002837 heart atrium Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000002731 stomach secretion inhibitor Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- SGXWMBXNTCVZPY-UHFFFAOYSA-N 1-(2,4-dimethylimidazol-1-yl)ethanone Chemical compound CC(=O)N1C=C(C)N=C1C SGXWMBXNTCVZPY-UHFFFAOYSA-N 0.000 description 2
- LLPKQRMDOFYSGZ-UHFFFAOYSA-N 2,5-dimethyl-1h-imidazole Chemical compound CC1=CN=C(C)N1 LLPKQRMDOFYSGZ-UHFFFAOYSA-N 0.000 description 2
- YQWRPDMPXIRUSH-UHFFFAOYSA-N 2-[4-(5-methyl-1h-imidazol-4-yl)-1,3-thiazol-2-yl]guanidine;hydrobromide Chemical compound Br.N1=CNC(C=2N=C(NC(N)=N)SC=2)=C1C YQWRPDMPXIRUSH-UHFFFAOYSA-N 0.000 description 2
- QJWIMGXDWBBGAN-UHFFFAOYSA-N 2-bromo-1-(2,5-dimethyl-1h-imidazol-4-yl)ethanone Chemical compound CC1=NC(C)=C(C(=O)CBr)N1 QJWIMGXDWBBGAN-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001262 anti-secretory effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- OSMJIXXVEWORDJ-UHFFFAOYSA-N 1-(1h-imidazol-2-yl)ethanone Chemical group CC(=O)C1=NC=CN1 OSMJIXXVEWORDJ-UHFFFAOYSA-N 0.000 description 1
- REQORQAFNBDQKR-UHFFFAOYSA-N 1-(2-methylimidazol-1-yl)ethanone Chemical compound CC(=O)N1C=CN=C1C REQORQAFNBDQKR-UHFFFAOYSA-N 0.000 description 1
- HUKNDBAKSCHISX-UHFFFAOYSA-N 1-(5-methyl-1h-imidazol-4-yl)ethanone Chemical compound CC(=O)C=1N=CNC=1C HUKNDBAKSCHISX-UHFFFAOYSA-N 0.000 description 1
- MGSUZKWFACFSDH-UHFFFAOYSA-N 1-[2-(hydroxymethyl)-1h-imidazol-5-yl]ethanone Chemical compound CC(=O)C1=CNC(CO)=N1 MGSUZKWFACFSDH-UHFFFAOYSA-N 0.000 description 1
- NYYVCPHBKQYINK-UHFFFAOYSA-N 1-ethyl-2-methylimidazole Chemical compound CCN1C=CN=C1C NYYVCPHBKQYINK-UHFFFAOYSA-N 0.000 description 1
- USILCGVVBNUZJO-UHFFFAOYSA-N 2-[4-(1h-imidazole-5-carbonyl)-1,3-thiazol-2-yl]guanidine Chemical compound S1C(NC(=N)N)=NC(C(=O)C=2N=CNC=2)=C1 USILCGVVBNUZJO-UHFFFAOYSA-N 0.000 description 1
- WVXRGBJXUZSUGQ-UHFFFAOYSA-N 2-[4-(1h-imidazole-5-carbonyl)-1,3-thiazol-2-yl]guanidine;hydrobromide Chemical compound Br.S1C(NC(=N)N)=NC(C(=O)C=2N=CNC=2)=C1 WVXRGBJXUZSUGQ-UHFFFAOYSA-N 0.000 description 1
- BZPHFGXTTYHSOU-UHFFFAOYSA-N 2-[4-(2,4-dimethylimidazol-4-yl)-1,3-thiazol-2-yl]guanidine;hydrobromide Chemical compound Br.C1=NC(C)=NC1(C)C1=CSC(NC(N)=N)=N1 BZPHFGXTTYHSOU-UHFFFAOYSA-N 0.000 description 1
- HNDQFQDOQPEQBR-UHFFFAOYSA-N 2-[4-(2-methyl-1h-imidazol-5-yl)-1,3-thiazol-2-yl]guanidine;hydrobromide Chemical compound Br.N1C(C)=NC(C=2N=C(NC(N)=N)SC=2)=C1 HNDQFQDOQPEQBR-UHFFFAOYSA-N 0.000 description 1
- LQXWVSXNRXFDKX-UHFFFAOYSA-N 2-[4-[2-(hydroxymethyl)-1h-imidazol-5-yl]-1,3-thiazol-2-yl]guanidine Chemical compound S1C(NC(=N)N)=NC(C=2N=C(CO)NC=2)=C1 LQXWVSXNRXFDKX-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- RFVGFNRMKXONPH-UHFFFAOYSA-N 2-bromo-1-(2-methyl-1h-imidazol-5-yl)ethanone Chemical compound CC1=NC(C(=O)CBr)=CN1 RFVGFNRMKXONPH-UHFFFAOYSA-N 0.000 description 1
- MVTGVDHNHMILAT-UHFFFAOYSA-N 2-bromo-1-(2-methyl-1h-imidazol-5-yl)ethanone;hydrobromide Chemical compound Br.CC1=NC(C(=O)CBr)=CN1 MVTGVDHNHMILAT-UHFFFAOYSA-N 0.000 description 1
- NHZTZQDWMOWTJF-UHFFFAOYSA-N 2-bromo-1-(5-methyl-1h-imidazol-4-yl)ethanone Chemical compound CC=1N=CNC=1C(=O)CBr NHZTZQDWMOWTJF-UHFFFAOYSA-N 0.000 description 1
- PSXFGGSTDYRXHA-UHFFFAOYSA-N 2-bromo-1-(5-methyl-1h-imidazol-4-yl)ethanone;hydrobromide Chemical compound Br.CC=1N=CNC=1C(=O)CBr PSXFGGSTDYRXHA-UHFFFAOYSA-N 0.000 description 1
- QTVGLOOZIYZYRQ-UHFFFAOYSA-N 2-bromo-1-[2-(hydroxymethyl)-1h-imidazol-5-yl]ethanone;hydrobromide Chemical compound Br.OCC1=NC(C(=O)CBr)=CN1 QTVGLOOZIYZYRQ-UHFFFAOYSA-N 0.000 description 1
- DMJVNZUWGQHJJB-UHFFFAOYSA-N 3-bromo-1-(1h-imidazol-5-yl)propane-1,2-dione;hydrobromide Chemical compound Br.BrCC(=O)C(=O)C1=CNC=N1 DMJVNZUWGQHJJB-UHFFFAOYSA-N 0.000 description 1
- RXXQKTSOBMGARS-UHFFFAOYSA-N 3-bromo-4-hydroxybut-3-en-2-one Chemical compound CC(=O)C(Br)=CO RXXQKTSOBMGARS-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- ISXOBTBCNRIIQO-UHFFFAOYSA-N tetrahydrothiophene 1-oxide Chemical compound O=S1CCCC1 ISXOBTBCNRIIQO-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19623180A | 1980-10-14 | 1980-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1217258A3 true SU1217258A3 (ru) | 1986-03-07 |
Family
ID=22724544
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU823491025A SU1311621A3 (ru) | 1980-10-14 | 1982-09-17 | Способ получени 2-гуанидино-4-триазолил-тиазолов |
| SU823495554A SU1205768A3 (ru) | 1980-10-14 | 1982-09-17 | Способ получени производных 2-гуанидино-4-тиазолилтиазола или их кислотно-аддитивных фармацевтически приемлемых солей |
| SU823493197A SU1217258A3 (ru) | 1980-10-14 | 1982-09-17 | Способ получени производных 2-гуанидино-4-гетероарилтиазола или их фармацевтически приемлемых кислотно-аддитивных солей |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU823491025A SU1311621A3 (ru) | 1980-10-14 | 1982-09-17 | Способ получени 2-гуанидино-4-триазолил-тиазолов |
| SU823495554A SU1205768A3 (ru) | 1980-10-14 | 1982-09-17 | Способ получени производных 2-гуанидино-4-тиазолилтиазола или их кислотно-аддитивных фармацевтически приемлемых солей |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS5795972A (enExample) |
| HU (2) | HU191496B (enExample) |
| IN (2) | IN163170B (enExample) |
| PL (1) | PL135097B1 (enExample) |
| SU (3) | SU1311621A3 (enExample) |
| ZA (1) | ZA817047B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2374224C2 (ru) * | 2003-05-06 | 2009-11-27 | Мерк Патент Гмбх | Способ кристаллизации солей гуанидиния |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997949A (en) * | 1986-10-29 | 1991-03-05 | Pfizer Inc. | Crystalline 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl) thiazole dihydrochloride trihydrate |
| IL95548A0 (en) * | 1989-09-15 | 1991-06-30 | Fujisawa Pharmaceutical Co | Thiazole derivatives,processes for the preparation thereof and pharmaceutical composition containing the same |
| JPWO2013146754A1 (ja) * | 2012-03-27 | 2015-12-14 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体 |
| CR20220325A (es) * | 2019-12-20 | 2022-08-19 | Tenaya Therapeutics Inc | Fluoroalquil-oxadiazoles y sus usos |
-
1981
- 1981-09-07 IN IN572/DEL/81A patent/IN163170B/en unknown
- 1981-10-13 HU HU833917A patent/HU191496B/hu not_active IP Right Cessation
- 1981-10-13 HU HU833916A patent/HU192826B/hu not_active IP Right Cessation
- 1981-10-13 JP JP56163370A patent/JPS5795972A/ja active Granted
- 1981-10-13 ZA ZA817047A patent/ZA817047B/xx unknown
- 1981-10-14 PL PL24164581A patent/PL135097B1/pl unknown
-
1982
- 1982-09-17 SU SU823491025A patent/SU1311621A3/ru active
- 1982-09-17 SU SU823495554A patent/SU1205768A3/ru active
- 1982-09-17 SU SU823493197A patent/SU1217258A3/ru active
-
1985
- 1985-02-13 IN IN120/DEL/85A patent/IN163394B/en unknown
Non-Patent Citations (1)
| Title |
|---|
| Гетероциклические соединени . Под ред. Л.Эльдерфильда. - М.: Иностранна литература, 1961, т.5, с..456-458. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2374224C2 (ru) * | 2003-05-06 | 2009-11-27 | Мерк Патент Гмбх | Способ кристаллизации солей гуанидиния |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5795972A (en) | 1982-06-15 |
| ZA817047B (en) | 1982-09-29 |
| SU1311621A3 (ru) | 1987-05-15 |
| HU191496B (en) | 1987-02-27 |
| HU192826B (en) | 1987-07-28 |
| PL135097B1 (en) | 1985-09-30 |
| JPS6157307B2 (enExample) | 1986-12-06 |
| IN163394B (enExample) | 1988-09-17 |
| IN163170B (enExample) | 1988-08-20 |
| PL241645A1 (en) | 1983-11-21 |
| SU1205768A3 (ru) | 1986-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI78695C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,2-diaminocyklobuten-3,4-dionderivat. | |
| KR960007524B1 (ko) | 치환된 이미다졸릴-알킬-피페라진 및 -디아제핀 유도체 | |
| US4616025A (en) | Thiazolidine derivatives, process for the preparation and pharmaceutical compositions thereof | |
| SU1153829A3 (ru) | Способ получени 2-гуанидино-4-имидазотиазолов или их фармацевтически приемлемых аддитивных солей кислот | |
| CH635586A5 (de) | Verfahren zur herstellung von 1,3-dihydroimidazo(4,5-b)pyridin-2-onen. | |
| SU1088665A3 (ru) | Способ получени производных N-(4-индолилпиперидиноалкил)-бензимидазолона или их солей с кислотами | |
| HU187478B (en) | Process for preparing new imidazolyl-phenyl-amidines and pharmaceutical compositions containing thereof | |
| SU1217258A3 (ru) | Способ получени производных 2-гуанидино-4-гетероарилтиазола или их фармацевтически приемлемых кислотно-аддитивных солей | |
| SU1195907A3 (ru) | Способ получени 2-гуанидино- 4-(2-замещенный амино-4-имидазолил)-тиазолов или их бромистоводородных солей и способ получени ацетилимидазола | |
| US4522943A (en) | Chemical compounds | |
| US4551466A (en) | Pyridyl-2-oxy-propyl-1H-1,2,4-triazole-3,5-diamines | |
| US4526973A (en) | Chemical compounds | |
| US4503051A (en) | Substituted 3-cyclobutene-1,2-diones, pharmaceutical compositions thereof and methods of use | |
| US4395553A (en) | Chemical compounds | |
| US4447611A (en) | Benzo-fused and heterocyclic fused imidazole anti-ulcer agents | |
| US4539316A (en) | Pyridine derivatives of 1,2-diaminocyclobutene-3,4-diones | |
| KR860000103B1 (ko) | 3'-치환-5'-(2-아미노-4-피리딜)-1', 2', 4'-트리아졸류의 제조 방법 | |
| US4738977A (en) | 2-pyridylacetic acid derivatives, pharmaceutical composition containing the same and their use in treating ulcers | |
| CA1051900A (en) | 1-hydroxymethyl-1-ethyl-1,2,3,4,6,7,12,12b-octahydroindolo(2,3-a)quinolizine compounds | |
| US4276297A (en) | Pyridylaminotriazole therapeutic agents | |
| US4546188A (en) | Substituted 1,2-diaminocyclobutene-3,4-diones | |
| US4590299A (en) | 2-guanidino-4-heteroarylthiazoles | |
| US4452987A (en) | Haloacetyl imidazoles | |
| US4788184A (en) | Substituted 3-cyclobutene-1,2-diones as anti-ulcer agents | |
| US4607105A (en) | 3-cyclobutene-1,2-dione intermediates |